Substitute for form 1449/PTO				Complete if Known			
				Application Number	10/829,504		
INFORMATION DISCLOSURE				Filing Date	April 21, 2004		
STATEMENT BY APPLICANT (Use as many sheets as necessary)			APPLICANT	First Named Inventor	David Epstein		
				Art Unit	1635		
			s necessary)	Examiner Name	R. A. Schnizer		
Sheet 1 of		1	Attorney Docket Number	23239-558 AUS			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>4</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear			

Examiner	Date	
Signature	Considered	

\*EXAMINE: Initial if reference considered, whether or not classion is in conformance with MEDE 600. Draw like intropy, classion if no incommence and not considered. Include copy of this form with west communication is applicant. "Applicant's unique sitestion designation number of recipions of the Conformation of USFTO Platent Documents at www.upplo.org or MIPEP 901 0A. "Enter Office that issued the document, by the short object of the Conformation of the Conform

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
	А	Martin-Orozco et al., "Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences", Intl. Immunol., 11(7):1111-1118 (1999)			
	В	Hartmann et al., "Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells", J. Immunol., 164:944-952 (2000)			
	С	Hartmann et al., "Cytokines and therapeutic oligonucleotides", Cell Mol. Ther., 3:247-256 (1997)			
	D	Hartmann et al., "Rational design of new CpG oligonucleotides that combine B cell activation with high IFN- $\alpha$ induction in plasmacytoid dendritic cells", <i>Eur. J. Immunol.</i> , 33:1633-1641 (2003)			

Date Considered	/Richard Schnizer/

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.